View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsAccelerate Diagnostics 将来の成長Future 基準チェック /06現在、 Accelerate Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Aug 19Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 08/18/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 06+ 1 more updateFinal DIP Financing Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court gave an order to Accelerate Diagnostics, Inc. to obtain DIP financing on final basis on June 5, 2025. As per the order, the debtor has been authorized to obtain a new money term loan facility in the amount of $12.5 million from Indaba Capital Fund, LP and Streeterville Capital LLC with U.S. Bank Trust Company, National Association as DIP agent. As per the terms of the DIP agreement, the loan carries a structuring fee of $1 million, exit fee of $7.5 million and earned in stages 35% at interim order, 15% at dip credit agreement and 50% at final dip order, backstop fee of $1.5 million. The DIP facility would mature either on December 31, 2025, or earliest of loan acceleration or closing of an asset sale, whichever is earlier. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out of $0.5 million towards unpaid professional fees / administrative expenses and first priority lien upon and security interest in the debtor’s collateral.お知らせ • May 17Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 05/16/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Accelerate Diagnostics, Inc.(OTCPK:AXDX.Q) dropped from NASDAQ Composite IndexAccelerate Diagnostics, Inc has been dropped from the NASDAQ Composite Indexお知らせ • May 13Accelerate Diagnostics Receives Delisting Determination and Minimum Bid Price Non-Compliance Letter from NasdaqAs previously disclosed, on May 8, 2025, Accelerate Diagnostics, Inc. (the “ Company”) and certain of its subsidiaries (together, the “ Debtors”) filed voluntary petitions (the “ Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “ Court” and such cases, the “ Cases”). On May 8, 2025, the Company received written notice (the “ Delisting Notice”) from the Listing Qualifications Staff (the “ Staff”) of The Nasdaq Stock Market LLC (“ Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff has determined that the Company’s common stock (the “ Securities”) will be delisted from Nasdaq. In addition, on May 6, 2025, the Company received written notice from the Staff notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement”). In the Delisting Notice, the Staff stated that its determination was based on (i) public interest concerns related to the Bankruptcy Petitions, (ii) concerns regarding the residual equity interest of the existing holders of listed Securities and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, the Staff noted that the Company was not in compliance with the Minimum Bid Price Requirement, nor in compliance with Nasdaq’s Market Value of Listed Securities (as defined under Nasdaq rules) requirement pursuant to Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Requirement”), as previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “ SEC”) on January 30, 2025. As a result, the Staff determined that the Company’s Minimum Bid Price Requirement and MVLS Requirement deficiencies served as an additional and separate basis for delisting. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal the determination and, therefore, it is expected that the Securities will be delisted. Trading of the Securities will be suspended at the opening of business on May 15, 2025 and a Form 25-NSE will be filed by Nasdaq with the SEC, which will remove the Securities from listing and registration on Nasdaq. The Company expects the Securities will begin trading on the over-the-counter (the “ OTC”) market under the symbol “AXDXQ” on May 15, 2025, but no assurance can be made that trading in the Securities on the OTC market will commence or be maintained.お知らせ • May 09+ 1 more updateMotion for Joint Administration Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of Accelerate Diagnostics, Inc. and its affiliates on May 8, 2025. The affiliates include Accelerate Diagnostics Texas, LLC. The cases would be jointly administered for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been designated as the lead debtor.お知らせ • May 08+ 1 more updateMotion for Joint Administration Filed by Accelerate Diagnostics, Inc.Accelerate Diagnostics, Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on May 8, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, Accelerate Diagnostics Texas, LLC, with its own case for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been proposed as the lead debtor.お知らせ • Apr 16Accelerate Diagnostics, Inc. Announces Director Appointments, Effective from April 10, 2025On April 10, 2025, the Board of Directors of Accelerate Diagnostics, Inc, unanimously elected Paul Shalhoub and Gilbert Nathan to serve as new directors, effective immediately. Messrs. Shalhoub and Nathan will serve as members of the Board until their successors are elected and qualified or until their earlier death, resignation, disqualification or removal. Mr. Nathan was proposed for election to the Board by certain holders pursuant to their director nomination rights under that certain note purchase agreement, dated August 8, 2024, relating to the Company’s 16.00% Super-Priority Senior Secured PIK Notes due 2025. The Board reviewed Mr. Nathan’s qualifications and unanimously agreed to his appointment. There are no transactions between the Company and either Messrs. Shalhoub or Nathan that would require disclosure under Item 404(a) of Regulation S-K. The Board has determined that Messrs. Shalhoub and Nathan are independent directors under the applicable rules of the Nasdaq Stock Market LLC.お知らせ • Mar 22Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceAccelerate Diagnostics, Inc. announced the submission of its Accelerate WAVE system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.5 hours, enabling same shift targeted antimicrobial therapy for patients with serious infections. With a user-friendly workflow, high throughput capacity, and scalable design, once approved by the FDA, the WAVE system will offer microbiology laboratories a comprehensive AST solution to meet a wide range of testing demands and hospital formulary needs. According to the World Health Organization, sepsis affects an estimated 49 million people globally each year, resulting in approximately 11 million deaths. Of those, around 1.32 million deaths are attributed to bacterial antimicrobial resistance. Sepsis also represents the most significant cost burden to the U.S. healthcare system, with an estimated annual expense of $62 billion. By delivering rapid AST results, the WAVE system is designed to support earlier, targeted antimicrobial therapy-- improving patient outcomes, reducing hospital costs, and helping combat antimicrobial resistance.お知らせ • Jan 30Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS RequirementOn January 28, 2025, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until July 28, 2025 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the Market Value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.お知らせ • Oct 01Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? SystemAccelerate Diagnostics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper®? CA System (MBT-CA System) and MBT-CA Sepsityper®? software extension. Designed for clinical laboratories, the Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification (ID) using Bruker's MBT-CA system. This eliminates the need for overnight culture methods, reducing the wait time for microbial ID results, which is critical in the fight against sepsis. The Accelerate Arc system is designed to leverage the breadth of the Bruker MBT-CA reference library to provide rapid ID. This, in conjunction with its future rapid phenotypic antibiotic susceptibility testing (AST) innovation, the Accelerate WAVE™ system1, can enable same shift reporting to Antimicrobial Stewardship teams and clinicians alike. By providing clinicians with rapid ID and AST results, clinicians can get the patient on the optimal antibiotic therapy many hours sooner, which has been shown to improve patient outcomes with Sepsis, reduce antimicrobial resistance rates and hospital costs. The Accelerate Arc system is also designed to supplant both overnight subculture as well as laborious Laboratory Developed Test (LDT) sample preparation methods. Clinical laboratories are under pressure to run FDA-cleared devices due to increased legislation and enforcement associated with the use of LDTs. Accordingly, such laboratories can now utilize the Accelerate Arc system as an automated, FDA-cleared system.お知らせ • Aug 09Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical TrialAccelerate Diagnostics, Inc. announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average. By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance. The pre-clinical trial included 1,570 WAVE results compared to Broth Microdilution ("BMD"), the reference method. The trial included an equal number of prospective patient samples and site selected challenge samples which resulted in excellent concordance between sample types. About the Accelerate WAVE System: The Accelerate WAVE system are intended to deliver same-shift antibiotic susceptibility test results enabling antimicrobial stewardship teams and clinicians alike to tailor therapy for patients with serious infections in a timely manner. Getting the patient on optimal therapy, as shown with numerous peer-reviewed publications, not only reduces morbidity associated with bacteremia but also reduces healthcare costs. The WAVE system will offer a comprehensive test menu and incorporates essential features to optimize workflow across laboratories. With full random access for continuous sample loading, the scalability of the Wave system addresses the needs of various health care settings from small community hospitals to large academic centers and reference labs. The WAVE System employs novel holographic imaging technology to determine bacterial growth and morphology changes in real time, enabling same-shift, quantitative usceptibility test results.お知らせ • May 03Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024Accelerate Diagnostics, Inc. announced that they will report Q1, 2024 results on May 08, 2024お知らせ • May 01Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of NasdaqOn April 26, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until October 23, 2024 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and close the matter. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff in writing of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.お知らせ • Apr 13Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024, at 10:30 Pacific Daylight. Agenda: To elect the following 9 persons to serve as directors of the Company (“Directors”) until the 2025 Annual Meeting of Shareholders or until their successors have been duly elected and qualified: Mark Black, Wayne C. Burris, Louise L. Francesconi, Hany Massarany, Marran H. Ogilvie, John Patience, Jack Phillips, Jennifer Regan, and Jack W. Schuler; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024; to approve an amendment to the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Incentive Plan”) to increase the total number of authorized shares of the Company’s common stock (“Shares”) available for grant thereunder by 4,000,000 Shares; and to transact such other business as may properly come before the meeting or any continuation, postponement or adjournment thereof.お知らせ • Mar 06Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLCOn March 4, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that for the last 31 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until September 3, 2024 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standards, such as by increasing its stockholders' equity to at least $2.5 million. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.お知らせ • Jan 25Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living TrustAccelerate Diagnostics, Inc. announced that it has entered into a securities purchase agreement to issue 33,332 units at a price of $1.5 per unit for the gross proceeds of $49,998 and 2,716,762 units at a price of $1.73 per unit for the gross proceeds of $4,699,998.26 for the total gross proceeds of $4,749,996 on January 25, 2024. The transaction will include participation from individual investors, Chief Executive Officer and Chief Financial Officer for $49,998 and returning investor, Jack W. Schuler Living Trust for $4,749,996. The transaction became effective as of May 20, 2024.お知らせ • Jan 21Accelerate Diagnostics, Inc. has completed a Composite Units Offering.Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.5 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.49お知らせ • Jul 11Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital MarketAccelerate Diagnostics, Inc. (the "Company") announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on July 11, 2023. The Company's common stock will begin trading on a post-split basis at the market open on July 12, 2023, under the Company's existing trading symbol "AXDX". The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 19, 2023 to be effected in the Board's discretion within approved parameters. The final ratio was approved by the Company's Board on July 7, 2023. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 144 million shares to approximately 14 million shares, subject to adjustment due to the payment of cash in lieu of fractional shares. As a result of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards, warrants and convertible notes and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable. There will be no change to the number of authorized shares or the par value per share.Reported Earnings • May 12First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2022)First quarter 2023 results: US$0.17 loss per share. Revenue: US$2.81m (down 4.9% from 1Q 2022). Net loss: US$16.8m (loss widened 18% from 1Q 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Global Medical Equipment industry.Reported Earnings • Mar 07Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share (further deteriorated from US$0.15 loss in 3Q 2021). Revenue: US$2.96m (down 5.2% from 3Q 2021). Net loss: US$15.9m (loss widened 77% from 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Global Medical Equipment industry.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. CEO, President & Director Jack Phillips was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jan 12Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price RequirementOn January 5, 2023, Accelerate Diagnostics, Inc. ("the Company") received a deficiency letter from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until July 5, 2023 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share (further deteriorated from US$0.15 loss in 3Q 2021). Revenue: US$2.96m (down 5.2% from 3Q 2021). Net loss: US$15.7m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Global Medical Equipment industry.Recent Insider Transactions • Aug 31Insider recently bought Mex$1.6m worth of stockOn the 30th of August, Larry Mertz bought around 50k shares on-market at roughly Mex$32.16 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$225m more in shares than they have sold in the last 12 months.Reported Earnings • Aug 16Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2021)Second quarter 2022 results: US$0.23 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$3.86m (up 38% from 2Q 2021). Net loss: US$17.8m (loss narrowed 18% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 19% growth forecast for the Medical Equipment industry in Mexico. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Reported Earnings • May 17First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.41 loss in 1Q 2021)First quarter 2022 results: US$0.21 loss per share (up from US$0.41 loss in 1Q 2021). Revenue: US$2.96m (up 18% from 1Q 2021). Net loss: US$14.2m (loss narrowed 42% from 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 17% growth forecast for the industry in Mexico. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Accelerate Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BMV:AXDX * - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202412-50-25-24N/A9/30/202412-53-27-27N/A6/30/202412-38-33-32N/A3/31/202412-59-37-35N/A12/31/202312-62-41-40N/A9/30/202312-63-43-42N/A6/30/202312-80-48-47N/A3/31/202313-66-50-49N/A12/31/202213-62-49-49N/A9/30/202213-71-52-51N/A6/30/202213-64-51-50N/A3/31/202212-67-48-47N/A12/31/202112-78-48-47N/A9/30/202112-74-46-46N/A6/30/202112-84-47-46N/A3/31/202111-81-47-46N/A12/31/202011-78-52-50N/A9/30/202012-81-55-54N/A6/30/202010-82-60-59N/A3/31/202010-84-64-63N/A12/31/20199-84-65-65N/A9/30/20198-85-66-65N/A6/30/20197-87-66-66N/A3/31/20197-89-71-71N/A12/31/20186-88-69-68N/A9/30/20186-82N/A-67N/A6/30/20185-77N/A-63N/A3/31/20184-71N/A-56N/A12/31/20174-64N/A-56N/A9/30/20172-64N/A-55N/A6/30/20171-64N/A-53N/A3/31/20171-65N/A-56N/A12/31/20160-66N/A-53N/A9/30/20160-63N/A-50N/A6/30/20160-57N/A-47N/A3/31/20160-52N/A-41N/A12/31/20150-45N/A-35N/A9/30/20150-41N/A-30N/A6/30/20150-39N/A-27N/A3/31/20150-35N/A-22N/A12/31/20140-31N/A-19N/A9/30/20140-27N/A-17N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AXDX *の予測収益成長が 貯蓄率 ( 8.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: AXDX *の収益がMX市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: AXDX *の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: AXDX *の収益がMX市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: AXDX *の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AXDX *の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/10 15:05終値2025/05/13 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Accelerate Diagnostics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sean LavinBTIGAlexander NowakCraig-Hallum Capital Group LLCTycho PetersonJ.P. Morgan1 その他のアナリストを表示
お知らせ • Aug 19Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 08/18/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 06+ 1 more updateFinal DIP Financing Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court gave an order to Accelerate Diagnostics, Inc. to obtain DIP financing on final basis on June 5, 2025. As per the order, the debtor has been authorized to obtain a new money term loan facility in the amount of $12.5 million from Indaba Capital Fund, LP and Streeterville Capital LLC with U.S. Bank Trust Company, National Association as DIP agent. As per the terms of the DIP agreement, the loan carries a structuring fee of $1 million, exit fee of $7.5 million and earned in stages 35% at interim order, 15% at dip credit agreement and 50% at final dip order, backstop fee of $1.5 million. The DIP facility would mature either on December 31, 2025, or earliest of loan acceleration or closing of an asset sale, whichever is earlier. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out of $0.5 million towards unpaid professional fees / administrative expenses and first priority lien upon and security interest in the debtor’s collateral.
お知らせ • May 17Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 05/16/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Accelerate Diagnostics, Inc.(OTCPK:AXDX.Q) dropped from NASDAQ Composite IndexAccelerate Diagnostics, Inc has been dropped from the NASDAQ Composite Index
お知らせ • May 13Accelerate Diagnostics Receives Delisting Determination and Minimum Bid Price Non-Compliance Letter from NasdaqAs previously disclosed, on May 8, 2025, Accelerate Diagnostics, Inc. (the “ Company”) and certain of its subsidiaries (together, the “ Debtors”) filed voluntary petitions (the “ Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “ Court” and such cases, the “ Cases”). On May 8, 2025, the Company received written notice (the “ Delisting Notice”) from the Listing Qualifications Staff (the “ Staff”) of The Nasdaq Stock Market LLC (“ Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff has determined that the Company’s common stock (the “ Securities”) will be delisted from Nasdaq. In addition, on May 6, 2025, the Company received written notice from the Staff notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement”). In the Delisting Notice, the Staff stated that its determination was based on (i) public interest concerns related to the Bankruptcy Petitions, (ii) concerns regarding the residual equity interest of the existing holders of listed Securities and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, the Staff noted that the Company was not in compliance with the Minimum Bid Price Requirement, nor in compliance with Nasdaq’s Market Value of Listed Securities (as defined under Nasdaq rules) requirement pursuant to Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Requirement”), as previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “ SEC”) on January 30, 2025. As a result, the Staff determined that the Company’s Minimum Bid Price Requirement and MVLS Requirement deficiencies served as an additional and separate basis for delisting. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal the determination and, therefore, it is expected that the Securities will be delisted. Trading of the Securities will be suspended at the opening of business on May 15, 2025 and a Form 25-NSE will be filed by Nasdaq with the SEC, which will remove the Securities from listing and registration on Nasdaq. The Company expects the Securities will begin trading on the over-the-counter (the “ OTC”) market under the symbol “AXDXQ” on May 15, 2025, but no assurance can be made that trading in the Securities on the OTC market will commence or be maintained.
お知らせ • May 09+ 1 more updateMotion for Joint Administration Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of Accelerate Diagnostics, Inc. and its affiliates on May 8, 2025. The affiliates include Accelerate Diagnostics Texas, LLC. The cases would be jointly administered for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been designated as the lead debtor.
お知らせ • May 08+ 1 more updateMotion for Joint Administration Filed by Accelerate Diagnostics, Inc.Accelerate Diagnostics, Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on May 8, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, Accelerate Diagnostics Texas, LLC, with its own case for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been proposed as the lead debtor.
お知らせ • Apr 16Accelerate Diagnostics, Inc. Announces Director Appointments, Effective from April 10, 2025On April 10, 2025, the Board of Directors of Accelerate Diagnostics, Inc, unanimously elected Paul Shalhoub and Gilbert Nathan to serve as new directors, effective immediately. Messrs. Shalhoub and Nathan will serve as members of the Board until their successors are elected and qualified or until their earlier death, resignation, disqualification or removal. Mr. Nathan was proposed for election to the Board by certain holders pursuant to their director nomination rights under that certain note purchase agreement, dated August 8, 2024, relating to the Company’s 16.00% Super-Priority Senior Secured PIK Notes due 2025. The Board reviewed Mr. Nathan’s qualifications and unanimously agreed to his appointment. There are no transactions between the Company and either Messrs. Shalhoub or Nathan that would require disclosure under Item 404(a) of Regulation S-K. The Board has determined that Messrs. Shalhoub and Nathan are independent directors under the applicable rules of the Nasdaq Stock Market LLC.
お知らせ • Mar 22Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceAccelerate Diagnostics, Inc. announced the submission of its Accelerate WAVE system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.5 hours, enabling same shift targeted antimicrobial therapy for patients with serious infections. With a user-friendly workflow, high throughput capacity, and scalable design, once approved by the FDA, the WAVE system will offer microbiology laboratories a comprehensive AST solution to meet a wide range of testing demands and hospital formulary needs. According to the World Health Organization, sepsis affects an estimated 49 million people globally each year, resulting in approximately 11 million deaths. Of those, around 1.32 million deaths are attributed to bacterial antimicrobial resistance. Sepsis also represents the most significant cost burden to the U.S. healthcare system, with an estimated annual expense of $62 billion. By delivering rapid AST results, the WAVE system is designed to support earlier, targeted antimicrobial therapy-- improving patient outcomes, reducing hospital costs, and helping combat antimicrobial resistance.
お知らせ • Jan 30Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS RequirementOn January 28, 2025, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until July 28, 2025 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the Market Value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.
お知らせ • Oct 01Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? SystemAccelerate Diagnostics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper®? CA System (MBT-CA System) and MBT-CA Sepsityper®? software extension. Designed for clinical laboratories, the Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification (ID) using Bruker's MBT-CA system. This eliminates the need for overnight culture methods, reducing the wait time for microbial ID results, which is critical in the fight against sepsis. The Accelerate Arc system is designed to leverage the breadth of the Bruker MBT-CA reference library to provide rapid ID. This, in conjunction with its future rapid phenotypic antibiotic susceptibility testing (AST) innovation, the Accelerate WAVE™ system1, can enable same shift reporting to Antimicrobial Stewardship teams and clinicians alike. By providing clinicians with rapid ID and AST results, clinicians can get the patient on the optimal antibiotic therapy many hours sooner, which has been shown to improve patient outcomes with Sepsis, reduce antimicrobial resistance rates and hospital costs. The Accelerate Arc system is also designed to supplant both overnight subculture as well as laborious Laboratory Developed Test (LDT) sample preparation methods. Clinical laboratories are under pressure to run FDA-cleared devices due to increased legislation and enforcement associated with the use of LDTs. Accordingly, such laboratories can now utilize the Accelerate Arc system as an automated, FDA-cleared system.
お知らせ • Aug 09Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical TrialAccelerate Diagnostics, Inc. announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average. By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance. The pre-clinical trial included 1,570 WAVE results compared to Broth Microdilution ("BMD"), the reference method. The trial included an equal number of prospective patient samples and site selected challenge samples which resulted in excellent concordance between sample types. About the Accelerate WAVE System: The Accelerate WAVE system are intended to deliver same-shift antibiotic susceptibility test results enabling antimicrobial stewardship teams and clinicians alike to tailor therapy for patients with serious infections in a timely manner. Getting the patient on optimal therapy, as shown with numerous peer-reviewed publications, not only reduces morbidity associated with bacteremia but also reduces healthcare costs. The WAVE system will offer a comprehensive test menu and incorporates essential features to optimize workflow across laboratories. With full random access for continuous sample loading, the scalability of the Wave system addresses the needs of various health care settings from small community hospitals to large academic centers and reference labs. The WAVE System employs novel holographic imaging technology to determine bacterial growth and morphology changes in real time, enabling same-shift, quantitative usceptibility test results.
お知らせ • May 03Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024Accelerate Diagnostics, Inc. announced that they will report Q1, 2024 results on May 08, 2024
お知らせ • May 01Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of NasdaqOn April 26, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until October 23, 2024 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and close the matter. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff in writing of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.
お知らせ • Apr 13Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024, at 10:30 Pacific Daylight. Agenda: To elect the following 9 persons to serve as directors of the Company (“Directors”) until the 2025 Annual Meeting of Shareholders or until their successors have been duly elected and qualified: Mark Black, Wayne C. Burris, Louise L. Francesconi, Hany Massarany, Marran H. Ogilvie, John Patience, Jack Phillips, Jennifer Regan, and Jack W. Schuler; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024; to approve an amendment to the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Incentive Plan”) to increase the total number of authorized shares of the Company’s common stock (“Shares”) available for grant thereunder by 4,000,000 Shares; and to transact such other business as may properly come before the meeting or any continuation, postponement or adjournment thereof.
お知らせ • Mar 06Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLCOn March 4, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that for the last 31 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until September 3, 2024 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standards, such as by increasing its stockholders' equity to at least $2.5 million. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.
お知らせ • Jan 25Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living TrustAccelerate Diagnostics, Inc. announced that it has entered into a securities purchase agreement to issue 33,332 units at a price of $1.5 per unit for the gross proceeds of $49,998 and 2,716,762 units at a price of $1.73 per unit for the gross proceeds of $4,699,998.26 for the total gross proceeds of $4,749,996 on January 25, 2024. The transaction will include participation from individual investors, Chief Executive Officer and Chief Financial Officer for $49,998 and returning investor, Jack W. Schuler Living Trust for $4,749,996. The transaction became effective as of May 20, 2024.
お知らせ • Jan 21Accelerate Diagnostics, Inc. has completed a Composite Units Offering.Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.5 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.49
お知らせ • Jul 11Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital MarketAccelerate Diagnostics, Inc. (the "Company") announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on July 11, 2023. The Company's common stock will begin trading on a post-split basis at the market open on July 12, 2023, under the Company's existing trading symbol "AXDX". The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 19, 2023 to be effected in the Board's discretion within approved parameters. The final ratio was approved by the Company's Board on July 7, 2023. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 144 million shares to approximately 14 million shares, subject to adjustment due to the payment of cash in lieu of fractional shares. As a result of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards, warrants and convertible notes and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable. There will be no change to the number of authorized shares or the par value per share.
Reported Earnings • May 12First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2022)First quarter 2023 results: US$0.17 loss per share. Revenue: US$2.81m (down 4.9% from 1Q 2022). Net loss: US$16.8m (loss widened 18% from 1Q 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Global Medical Equipment industry.
Reported Earnings • Mar 07Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share (further deteriorated from US$0.15 loss in 3Q 2021). Revenue: US$2.96m (down 5.2% from 3Q 2021). Net loss: US$15.9m (loss widened 77% from 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Global Medical Equipment industry.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. CEO, President & Director Jack Phillips was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jan 12Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price RequirementOn January 5, 2023, Accelerate Diagnostics, Inc. ("the Company") received a deficiency letter from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until July 5, 2023 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.
Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share (further deteriorated from US$0.15 loss in 3Q 2021). Revenue: US$2.96m (down 5.2% from 3Q 2021). Net loss: US$15.7m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Global Medical Equipment industry.
Recent Insider Transactions • Aug 31Insider recently bought Mex$1.6m worth of stockOn the 30th of August, Larry Mertz bought around 50k shares on-market at roughly Mex$32.16 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$225m more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 16Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2021)Second quarter 2022 results: US$0.23 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$3.86m (up 38% from 2Q 2021). Net loss: US$17.8m (loss narrowed 18% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 19% growth forecast for the Medical Equipment industry in Mexico. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Reported Earnings • May 17First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.41 loss in 1Q 2021)First quarter 2022 results: US$0.21 loss per share (up from US$0.41 loss in 1Q 2021). Revenue: US$2.96m (up 18% from 1Q 2021). Net loss: US$14.2m (loss narrowed 42% from 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 17% growth forecast for the industry in Mexico.